Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer

Abstract Background PARP inhibitors (PARPi) benefit only a fraction of breast cancer patients with BRCA mutations, and their efficacy is even more limited in triple-negative breast cancer (TNBC) due to clinical primary and acquired resistance. Here, we found that the efficacy of the PARPi olaparib i...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Xiuzhi Zhu, Li Chen, Binhao Huang, Xiaoguang Li, Liu Yang, Xin Hu, Yizhou Jiang, Zhimin Shao, Zhonghua Wang
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2021-04-01
Serie:	Journal of Experimental & Clinical Cancer Research
Soggetti:	Triple-negative breast cancer PARP inhibitors CDK4/6 inhibitors Wnt signalling pathway Resistance
Accesso online:	https://doi.org/10.1186/s13046-021-01930-w
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!